<p>強生（NYSE:JNJ - 獲取免費報告）週五交易中股價上漲了 0.9%。該股最高交易價為 151.46 美元，最後交易價為 150.93 美元。交易期間約有 2,046,255 股被交易，較平均每日交易量 7,919,047 股下降了 74%。該股此前收盤價為 149.61 美元。</p>
<p>獲取 <strong>強生</strong> 的提醒：</p>
<h2>分析師評級變動</h2>
<ul>
<li>3 家行業巨頭正在通過提高股息來回報投資者</li>
</ul>
<p>強生的股票曾受到多份分析師報告的關注。摩根士丹利將強生的目標股價從 164.00 美元上調至 169.00 美元，並在 4 月 16 日的報告中給予該公司 “持平” 評級。Stifel Nicolaus 將強生的目標股價從 170.00 美元下調至 155.00 美元，並在 1 月 23 日的報告中對該公司給予 “持有” 評級。桑福德·伯恩斯坦在 4 月 16 日的報告中重申了對強生股票的 “市場表現” 評級。Leerink Partners 將強生的評級從 “跑贏大盤” 下調至 “市場表現”，並在週二的報告中將該股的目標價從 169.00 美元下調至 153.00 美元。最後，富國銀行將強生的目標價從 166.00 美元下調至 152.00 美元，並在 1 月 23 日的報告中給予該公司 “持平” 評級。共有 11 位股票研究分析師對該股給予 “持有” 評級，7 位給予 “買入” 評級，3 位給予 “強烈買入” 評級。根據 MarketBeat 的數據，強生目前的共識評級為 “適度買入”，共識目標價為 170.88 美元。</p>
<p><strong>閲讀我們關於強生的最新研究報告</strong></p>
<h2>強生股票上漲 1.1%</h2>
<ul>
<li>3 只頂級大型製藥股在美國投資超過 1000 億美元</li>
</ul>
<p>該公司的 50 日移動平均線為 156.56 美元，200 日移動平均線為 154.00 美元。該公司的市值為 3640.5 億美元，市盈率為 22.76，市盈增長比率為 2.56，貝塔值為 0.42。該公司的債務股本比率為 0.43，速動比率為 0.86，流動比率為 1.11。</p>
<p>強生（NYSE:JNJ - 獲取免費報告）最近一次公佈季度財報是在 4 月 15 日。該公司報告季度每股收益為 2.77 美元，超出市場共識預期的 2.59 美元，超出幅度為 0.18 美元。該公司季度收入為 218.9 億美元，而市場共識預期為 216.5 億美元。強生的股本回報率為 34.24%，淨利潤率為 18.20%。分析師預計強生在當前財政年度的每股收益將達到 10.58 美元。</p>
<h2>強生增加股息</h2>
<ul>
<li>強生的收益好於壞——現在是買入的時候嗎？</li>
</ul>
<p>該公司最近宣佈了季度股息，將於 6 月 10 日支付。5 月 27 日的股東將獲得 1.30 美元的股息。該股息的除息日為 5 月 27 日。這比強生之前的季度股息 1.24 美元有所增加。這相當於年化股息 5.20 美元，收益率為 3.44%。強生的股息支付比率（DPR）為 57.84%。</p>
<h2>強生的內部交易</h2>
<p>在相關消息中，副總裁羅伯特·J·德克爾於 2 月 25 日出售了 6,999 股公司的股票，交易價格為 165.88 美元，總交易額為 1,160,994.12 美元。出售後，該副總裁現在直接持有 21,001 股公司股票，價值為 3,483,645.88 美元。這筆交易代表其持股減少了 25.00%。該交易已在證券交易委員會的法律文件中披露，相關文件可在此鏈接查看。此外，執行副總裁蒂莫西·施密德於 2 月 18 日出售了 403 股公司的股票，交易價格為 156.15 美元，總價值為 62,928.45 美元。出售完成後，該執行副總裁現在直接持有 15,098 股公司股票，價值約為 2,357,552.70 美元。這筆交易使其持股減少了 2.60%。該交易的披露信息可以在這裏找到。公司內部人士目前持有該股的 0.16%。</p>
<h2>強生的機構交易</h2>
<p>機構投資者最近對該公司的持倉進行了調整。IFS Advisors LLC 在第四季度將其在強生股票中的持倉增加了 138.9%。IFS Advisors LLC 現在擁有 172 股公司股票，價值 25,000 美元，此前在上個季度增持了 100 股。WealthTrak Capital Management LLC 在第四季度購買了強生的新股份，價值約為 26,000 美元。Mountain Hill Investment Partners Corp.在第四季度購買了強生的新股份，價值約為 29,000 美元。Bay Harbor Wealth Management LLC 在第四季度購買了強生的新股份，價值約為 32,000 美元。最後，Conquis Financial LLC 在第四季度購買了強生的新股份，價值約為 33,000 美元。69.55% 的股票由機構投資者和對沖基金持有。</p>
<h2>強生公司簡介</h2>
<p>（獲取免費報告）</p>
<p>強生是一家控股公司，專注於醫療領域的產品研究、開發、生產和銷售。它通過創新藥物和醫療技術兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
<h2>特色文章</h2>
<ul>
<li>我們更看好的五隻股票超過強生</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>Meta 的 AI 增長五大關鍵支柱——扎克伯格的大膽願景</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>零售投資者正在大舉押注火箭實驗室——你也應該這樣做嗎？</li>
<li>多元化可以平滑收益並降低投資組合風險</li>
<li>通用電氣航空：卡塔爾交易推動數十億美元的增長引擎</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元於強生嗎？</h2>
<p>在考慮強生之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而強生並不在名單上。</p>
<p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

強生

<p>強生（NYSE: JNJ）股價上漲 0.9%，至 150.93 美元，交易量約為 200 萬股。分析師意見不一，摩根士丹利將其目標價上調至 169 美元，而 Stifel Nicolaus 則下調至 155 美元。公司報告季度每股收益（EPS）為 2.77 美元，超出預期，並宣佈每股股息增加至 1.30 美元。該股票市值為 3640.5 億美元，市場共識評級為 “適度買入”</p>

<p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report)'s share price was up 0.9% during trading on Friday . The stock traded as high as $151.46 and last traded at $150.93. Approximately 2,046,255 shares were traded during trading, a decline of 74% from the average daily volume of 7,919,047 shares. The stock had previously closed at $149.61.</p>
<div class="lb-trans"><p>強生（NYSE:JNJ - 獲取免費報告）週五交易中股價上漲了 0.9%。該股最高交易價為 151.46 美元，最後交易價為 150.93 美元。交易期間約有 2,046,255 股被交易，較平均每日交易量 7,919,047 股下降了 74%。該股此前收盤價為 149.61 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>強生</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>3 Industry Behemoths Are Rewarding Investors With Dividend Bumps</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家行業巨頭正在通過提高股息來回報投資者</li>
</ul>
</div><p>JNJ has been the subject of several analyst reports. Morgan Stanley raised their price target on Johnson &amp; Johnson from $164.00 to $169.00 and gave the company an &#34;equal weight&#34; rating in a report on Wednesday, April 16th. Stifel Nicolaus reduced their price objective on Johnson &amp; Johnson from $170.00 to $155.00 and set a &#34;hold&#34; rating for the company in a report on Thursday, January 23rd. Sanford C. Bernstein reiterated a &#34;market perform&#34; rating on shares of Johnson &amp; Johnson in a report on Wednesday, April 16th. Leerink Partners downgraded Johnson &amp; Johnson from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and reduced their price objective for the stock from $169.00 to $153.00 in a report on Tuesday. Finally, Wells Fargo &amp; Company reduced their price objective on Johnson &amp; Johnson from $166.00 to $152.00 and set an &#34;equal weight&#34; rating for the company in a report on Thursday, January 23rd. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Johnson &amp; Johnson currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $170.88.</p>
<div class="lb-trans"><p>強生的股票曾受到多份分析師報告的關注。摩根士丹利將強生的目標股價從 164.00 美元上調至 169.00 美元，並在 4 月 16 日的報告中給予該公司 “持平” 評級。Stifel Nicolaus 將強生的目標股價從 170.00 美元下調至 155.00 美元，並在 1 月 23 日的報告中對該公司給予 “持有” 評級。桑福德·伯恩斯坦在 4 月 16 日的報告中重申了對強生股票的 “市場表現” 評級。Leerink Partners 將強生的評級從 “跑贏大盤” 下調至 “市場表現”，並在週二的報告中將該股的目標價從 169.00 美元下調至 153.00 美元。最後，富國銀行將強生的目標價從 166.00 美元下調至 152.00 美元，並在 1 月 23 日的報告中給予該公司 “持平” 評級。共有 11 位股票研究分析師對該股給予 “持有” 評級，7 位給予 “買入” 評級，3 位給予 “強烈買入” 評級。根據 MarketBeat 的數據，強生目前的共識評級為 “適度買入”，共識目標價為 170.88 美元。</p>
</div><p><strong>Read Our Latest Research Report on Johnson &amp; Johnson</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於強生的最新研究報告</strong></p>
</div><h2>Johnson &amp; Johnson Stock Up 1.1%</h2>
<div class="lb-trans"><h2>強生股票上漲 1.1%</h2>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只頂級大型製藥股在美國投資超過 1000 億美元</li>
</ul>
</div><p>The company has a fifty day moving average of $156.56 and a two-hundred day moving average of $154.00. The company has a market cap of $364.05 billion, a PE ratio of 22.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為 156.56 美元，200 日移動平均線為 154.00 美元。該公司的市值為 3640.5 億美元，市盈率為 22.76，市盈增長比率為 2.56，貝塔值為 0.42。該公司的債務股本比率為 0.43，速動比率為 0.86，流動比率為 1.11。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson &amp; Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, analysts anticipate that Johnson &amp; Johnson will post 10.58 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>強生（NYSE:JNJ - 獲取免費報告）最近一次公佈季度財報是在 4 月 15 日。該公司報告季度每股收益為 2.77 美元，超出市場共識預期的 2.59 美元，超出幅度為 0.18 美元。該公司季度收入為 218.9 億美元，而市場共識預期為 216.5 億美元。強生的股本回報率為 34.24%，淨利潤率為 18.20%。分析師預計強生在當前財政年度的每股收益將達到 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Increases Dividend</h2>
<div class="lb-trans"><h2>強生增加股息</h2>
</div><ul>
<li>Johnson &amp; Johnson Earnings Were More Good Than Bad—Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>強生的收益好於壞——現在是買入的時候嗎？</li>
</ul>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, May 27th. This is a boost from Johnson &amp; Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.44%. Johnson &amp; Johnson's dividend payout ratio (DPR) is 57.84%.</p>
<div class="lb-trans"><p>該公司最近宣佈了季度股息，將於 6 月 10 日支付。5 月 27 日的股東將獲得 1.30 美元的股息。該股息的除息日為 5 月 27 日。這比強生之前的季度股息 1.24 美元有所增加。這相當於年化股息 5.20 美元，收益率為 3.44%。強生的股息支付比率（DPR）為 57.84%。</p>
</div><h2>Insider Buying and Selling at Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>強生的內部交易</h2>
</div><p>In related news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. This trade represents a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，副總裁羅伯特·J·德克爾於 2 月 25 日出售了 6,999 股公司的股票，交易價格為 165.88 美元，總交易額為 1,160,994.12 美元。出售後，該副總裁現在直接持有 21,001 股公司股票，價值為 3,483,645.88 美元。這筆交易代表其持股減少了 25.00%。該交易已在證券交易委員會的法律文件中披露，相關文件可在此鏈接查看。此外，執行副總裁蒂莫西·施密德於 2 月 18 日出售了 403 股公司的股票，交易價格為 156.15 美元，總價值為 62,928.45 美元。出售完成後，該執行副總裁現在直接持有 15,098 股公司股票，價值約為 2,357,552.70 美元。這筆交易使其持股減少了 2.60%。該交易的披露信息可以在這裏找到。公司內部人士目前持有該股的 0.16%。</p>
</div><h2>Institutional Trading of Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>強生的機構交易</h2>
</div><p>Institutional investors have recently made changes to their positions in the company. IFS Advisors LLC boosted its position in shares of Johnson &amp; Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after acquiring an additional 100 shares in the last quarter. WealthTrak Capital Management LLC purchased a new stake in Johnson &amp; Johnson during the 4th quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson &amp; Johnson during the 4th quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC purchased a new stake in Johnson &amp; Johnson during the 4th quarter valued at approximately $32,000. Finally, Conquis Financial LLC purchased a new stake in Johnson &amp; Johnson during the 4th quarter valued at approximately $33,000. 69.55% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>機構投資者最近對該公司的持倉進行了調整。IFS Advisors LLC 在第四季度將其在強生股票中的持倉增加了 138.9%。IFS Advisors LLC 現在擁有 172 股公司股票，價值 25,000 美元，此前在上個季度增持了 100 股。WealthTrak Capital Management LLC 在第四季度購買了強生的新股份，價值約為 26,000 美元。Mountain Hill Investment Partners Corp.在第四季度購買了強生的新股份，價值約為 29,000 美元。Bay Harbor Wealth Management LLC 在第四季度購買了強生的新股份，價值約為 32,000 美元。最後，Conquis Financial LLC 在第四季度購買了強生的新股份，價值約為 33,000 美元。69.55% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>強生公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>強生是一家控股公司，專注於醫療領域的產品研究、開發、生產和銷售。它通過創新藥物和醫療技術兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>Retail Investors Are Betting Big on Rocket Lab—Should You Too?</li>
<li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li>
<li>GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過強生</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>Meta 的 AI 增長五大關鍵支柱——扎克伯格的大膽願景</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>零售投資者正在大舉押注火箭實驗室——你也應該這樣做嗎？</li>
<li>多元化可以平滑收益並降低投資組合風險</li>
<li>通用電氣航空：卡塔爾交易推動數十億美元的增長引擎</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元於強生嗎？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮強生之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而強生並不在名單上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

強生（NYSE:JNJ）股價上漲 0.9% - 以下是原因